Twin Capital Management Inc. Invests $878,000 in Alnylam Pharmaceuticals, Inc. $ALNY

Twin Capital Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,208 shares of the biopharmaceutical company’s stock, valued at approximately $878,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ALNY. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $243,000. Geneos Wealth Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 175 shares during the period. Flow Traders U.S. LLC bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $241,000. Daiwa Securities Group Inc. increased its stake in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares during the period. Finally, NewEdge Advisors LLC increased its stake in Alnylam Pharmaceuticals by 70,300.0% in the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 703 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $722,795.90. Following the transaction, the executive vice president directly owned 64,273 shares in the company, valued at $21,059,048.45. This represents a 3.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the transaction, the executive vice president owned 21,860 shares in the company, valued at $6,989,297.80. This represents a 7.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 21,255 shares of company stock valued at $6,930,337 over the last three months. 0.86% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of analyst reports. Chardan Capital reissued a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 target price on the stock. Finally, Truist Financial decreased their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $300.51 on Friday. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $40.12 billion, a price-to-earnings ratio of 82.11 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 1-year low of $284.19 and a 1-year high of $495.55. The firm’s 50-day moving average price is $311.62 and its two-hundred day moving average price is $359.92.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the business earned ($0.44) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 96.4% on a year-over-year basis. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.